ALPMY - 3 Things In Biotech July 16: Array Gets An Important Update
Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research.
Array's melanoma combo gets a guideline nod
Company: Array Biopharma (ARRY)
Therapy: Enorafenib and binimetinib
Disease: Metastatic melanoma
News: ARRY announced that their combination therapy of encorafenib and binimetinib, recently approved for metastatic melanoma, has been included in the NCCN Guidelines for melanoma as a Category 1 recommendation for first- and second-line treatment for patients with BRAF-mutant metastatic melanoma. This indicates